JP2009510165A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009510165A5 JP2009510165A5 JP2008534614A JP2008534614A JP2009510165A5 JP 2009510165 A5 JP2009510165 A5 JP 2009510165A5 JP 2008534614 A JP2008534614 A JP 2008534614A JP 2008534614 A JP2008534614 A JP 2008534614A JP 2009510165 A5 JP2009510165 A5 JP 2009510165A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cells
- composition according
- agent
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 39
- 210000004027 cell Anatomy 0.000 claims 16
- 206010021143 Hypoxia Diseases 0.000 claims 11
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 230000001146 hypoxic effect Effects 0.000 claims 10
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 8
- 210000001185 bone marrow Anatomy 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- OJYIBEYSBXIQOP-UHFFFAOYSA-N 1-methoxy-4-[2-(4-methoxyphenyl)propan-2-yl]benzene Chemical compound C1=CC(OC)=CC=C1C(C)(C)C1=CC=C(OC)C=C1 OJYIBEYSBXIQOP-UHFFFAOYSA-N 0.000 claims 2
- 241000219198 Brassica Species 0.000 claims 2
- 235000003351 Brassica cretica Nutrition 0.000 claims 2
- 235000003343 Brassica rupestris Nutrition 0.000 claims 2
- OQQVFCKUDYMWGV-UHFFFAOYSA-N [5-[1-(phenylmethyl)-3-indazolyl]-2-furanyl]methanol Chemical compound O1C(CO)=CC=C1C(C1=CC=CC=C11)=NN1CC1=CC=CC=C1 OQQVFCKUDYMWGV-UHFFFAOYSA-N 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 claims 2
- 210000000601 blood cell Anatomy 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 230000000779 depleting effect Effects 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 235000010460 mustard Nutrition 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- QVMPZNRFXAKISM-UHFFFAOYSA-N tirapazamine Chemical group C1=CC=C2[N+]([O-])=NC(=N)N(O)C2=C1 QVMPZNRFXAKISM-UHFFFAOYSA-N 0.000 claims 2
- 229950002376 tirapazamine Drugs 0.000 claims 2
- OWQPOVKKUWUEKE-UHFFFAOYSA-N 1,2,3-benzotriazine Chemical compound N1=NN=CC2=CC=CC=C21 OWQPOVKKUWUEKE-UHFFFAOYSA-N 0.000 claims 1
- KIMCGLHTSSZPNS-UHFFFAOYSA-N 2,3-dinitrobenzamide Chemical compound NC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O KIMCGLHTSSZPNS-UHFFFAOYSA-N 0.000 claims 1
- YZBAXVICWUUHGG-UHFFFAOYSA-N 2-[[4-[2-[dimethyl(oxido)azaniumyl]ethylamino]-5,8-dihydroxy-9,10-dioxoanthracen-1-yl]amino]-n,n-dimethylethanamine oxide Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCC[N+](C)(C)[O-])=CC=C2NCC[N+](C)([O-])C YZBAXVICWUUHGG-UHFFFAOYSA-N 0.000 claims 1
- XPBJPGMCFKYBBV-UHFFFAOYSA-N 2-bromoethyl-[2-hydroxy-3-(2-nitroimidazol-1-yl)propyl]azanium;bromide Chemical compound Br.BrCCNCC(O)CN1C=CN=C1[N+]([O-])=O XPBJPGMCFKYBBV-UHFFFAOYSA-N 0.000 claims 1
- OFUFXTHGZWIDDB-UHFFFAOYSA-N 2-chloroquinoline Chemical compound C1=CC=CC2=NC(Cl)=CC=C21 OFUFXTHGZWIDDB-UHFFFAOYSA-N 0.000 claims 1
- YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical compound [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 claims 1
- DQMALWRRERBILB-UHFFFAOYSA-N 5-[bis-2(chloro-ethyl)-amino]-2,4-dintro-benzamide Chemical compound NC(=O)C1=CC(N(CCCl)CCCl)=C([N+]([O-])=O)C=C1[N+]([O-])=O DQMALWRRERBILB-UHFFFAOYSA-N 0.000 claims 1
- LWTUZIMLIKOKDI-UHFFFAOYSA-N 7-chloro-n-[3-(2-nitroimidazol-1-yl)propyl]quinolin-4-amine;hydrochloride Chemical compound Cl.[O-][N+](=O)C1=NC=CN1CCCNC1=CC=NC2=CC(Cl)=CC=C12 LWTUZIMLIKOKDI-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 101710183280 Topoisomerase Proteins 0.000 claims 1
- OZNRZINTTRZGCV-UHFFFAOYSA-N [nitro(phenyl)methoxy]phosphonamidic acid Chemical compound NP(O)(=O)OC([N+]([O-])=O)C1=CC=CC=C1 OZNRZINTTRZGCV-UHFFFAOYSA-N 0.000 claims 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 claims 1
- 150000004056 anthraquinones Chemical class 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- JAWGVVJVYSANRY-UHFFFAOYSA-N cobalt(3+) Chemical group [Co+3] JAWGVVJVYSANRY-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 210000004700 fetal blood Anatomy 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 230000006058 immune tolerance Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- IGGVVGHJSQSLFO-UHFFFAOYSA-N indole-5,6-quinone Chemical compound O=C1C(=O)C=C2C=CNC2=C1 IGGVVGHJSQSLFO-UHFFFAOYSA-N 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- OBBCSXFCDPPXOL-UHFFFAOYSA-N misonidazole Chemical compound COCC(O)CN1C=CN=C1[N+]([O-])=O OBBCSXFCDPPXOL-UHFFFAOYSA-N 0.000 claims 1
- 229950010514 misonidazole Drugs 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 150000003839 salts Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72318305P | 2005-10-03 | 2005-10-03 | |
| PCT/US2006/038553 WO2007041546A2 (en) | 2005-10-03 | 2006-09-29 | Method for selectively depleting hypoxic cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009510165A JP2009510165A (ja) | 2009-03-12 |
| JP2009510165A5 true JP2009510165A5 (enExample) | 2009-11-05 |
Family
ID=37826084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008534614A Pending JP2009510165A (ja) | 2005-10-03 | 2006-09-29 | 低酸素細胞を選択的に枯渇させるための方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20090136521A1 (enExample) |
| EP (1) | EP1931769A2 (enExample) |
| JP (1) | JP2009510165A (enExample) |
| CA (1) | CA2624707A1 (enExample) |
| WO (1) | WO2007041546A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8003625B2 (en) | 2005-06-29 | 2011-08-23 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs |
| NZ549831A (en) * | 2006-09-11 | 2009-03-31 | Auckland Uniservices Ltd | Combination of docetaxel and a nitrophenyl phosphate derivative for the treatment of cancer |
| WO2008033039A1 (en) * | 2006-09-11 | 2008-03-20 | Adam Vorn Patterson | Cancer treatment |
| WO2009067489A1 (en) * | 2007-11-20 | 2009-05-28 | Lankenau Institute For Medical Research | Disulfide chemotherapeutic agents and methods of use thereof |
| CN101683319B (zh) * | 2008-09-24 | 2012-09-05 | 杭州民生药业有限公司 | 一种替拉扎明非肠道给药含水制剂及其制备方法 |
| EP2350664B1 (en) * | 2008-10-21 | 2021-05-19 | ImmunoGenesis, Inc. | Treatment of cancer using the hypoxia activated prodrug th-302 in combination with docetaxel or pemetrexed |
| US8697391B2 (en) | 2009-05-15 | 2014-04-15 | Lankenau Institute For Medical Research | Method of determining cell number or viability using hydroxyethyldisulfide |
| US8269197B2 (en) | 2009-07-22 | 2012-09-18 | Intraop Medical Corporation | Method and system for electron beam applications |
| EP2542307A4 (en) | 2010-03-01 | 2013-10-09 | Intraop Medical Corp | COMBINED RADIOTHERAPY WITH HYPOXIC CELL SENSITILIZERS |
| US20140010805A1 (en) | 2010-07-12 | 2014-01-09 | Karen Curd | Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer |
| US9254299B2 (en) | 2011-12-22 | 2016-02-09 | Threshold Pharmaceuticals, Inc. | Administration of hypoxia activated prodrugs in combination with Chk1 inhibitors for treating cancer |
| US9278124B2 (en) | 2012-10-16 | 2016-03-08 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
| JP2016528217A (ja) | 2013-07-26 | 2016-09-15 | スレッショルド ファーマシューティカルズ，インコーポレイテッド | 低酸素活性化プロドラッグおよびタキサンの組合せを用いた膵臓癌の治療 |
| US9808011B2 (en) | 2014-12-15 | 2017-11-07 | Biovectra Inc. | Pentacyclic triterpene compounds and uses thereof |
| AU2016282785A1 (en) | 2015-06-24 | 2018-02-15 | Immunogenesis, Inc. | Aziridine containing DNA alkylating agents |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE794742A (fr) * | 1972-02-01 | 1973-07-30 | Bayer Ag | Nouveaux di-n-oxydes (1,4) de benzo-1,2,4-triazine, leur procede de preparation et leur application comme medicaments et additifs de nutrition |
| US3957779A (en) * | 1972-11-15 | 1976-05-18 | Bayer Aktiengesellschaft | Benzo-1,2,4-triazines |
| US5175287A (en) * | 1986-09-25 | 1992-12-29 | S R I International | Process for preparing 1,2,4-benzotriazine oxides |
| US5484612A (en) * | 1993-09-22 | 1996-01-16 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin |
| US5672702A (en) * | 1995-12-04 | 1997-09-30 | Sanofi | Process for preparing 3 amino 1, 2, 4-benzotriazine dioxide |
| AU6178198A (en) * | 1997-03-07 | 1998-09-22 | Sanofi Pharmaceuticals, Inc. | Method of treating a tumor |
| JP2002505341A (ja) * | 1998-03-06 | 2002-02-19 | オックスフォード バイオメディカ（ユーケイ）リミテッド | プロドラッグの活性化の増強 |
-
2006
- 2006-09-29 CA CA002624707A patent/CA2624707A1/en not_active Abandoned
- 2006-09-29 US US11/992,898 patent/US20090136521A1/en not_active Abandoned
- 2006-09-29 JP JP2008534614A patent/JP2009510165A/ja active Pending
- 2006-09-29 EP EP06816085A patent/EP1931769A2/en not_active Withdrawn
- 2006-09-29 WO PCT/US2006/038553 patent/WO2007041546A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Beatty et al. | The biological underpinnings of therapeutic resistance in pancreatic cancer | |
| US12098139B2 (en) | Chemokine receptor modulators and uses thereof | |
| US11433137B2 (en) | Compounds for treating cancer | |
| US10604526B2 (en) | Chemokine receptor modulators and uses thereof | |
| US20250042922A1 (en) | Kras modulating compounds | |
| Zhang et al. | Targeting role of glioma stem cells for gliobastoma multiforme | |
| Yotnda et al. | Hypoxic tumors and their effect on immune cells and cancer therapy | |
| JP2015534946A5 (enExample) | ||
| TWI641374B (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| US20180072743A1 (en) | Chemokine receptor modulators and uses thereof | |
| JP2019515908A5 (enExample) | ||
| Shi et al. | An overview of heavy chain ferritin in cancer | |
| US20220274964A1 (en) | 5-bromo-indirubins | |
| US12240837B2 (en) | Chemokine receptor modulators and uses thereof | |
| CN111789868A (zh) | 青蒿素类化合物在促进嵌合抗原受体t细胞治疗中的应用及药物组合物 | |
| JP2009538935A5 (enExample) | ||
| CN118903175A (zh) | 小分子药物联用在增强低氧条件下nk细胞的代谢、杀伤能力中的应用 | |
| JP2016502527A5 (enExample) | ||
| CN104147036B (zh) | 地西他滨和奥沙利铂在制备治疗肾细胞癌组合药物中应用 | |
| US20190060330A1 (en) | Application of 4-hydroxy salicylanilide in preparation of anti-myeloma or anti-lymphoma drugs | |
| Wang et al. | IDDF2022-ABS-0176 Tumor-derived iron loaded-exosomes impair CD8+ T anti-tumor ability via ferroptosis in hepatocellular carcinoma | |
| Yang et al. | Dual targeting of MEK and PI3K pathways can act via tumor-intrinsic mechanisms to overcome resistance and tumor-extrinsic mechanisms to modulate immunity and limit cancer cachexia | |
| Alshaker et al. | PO-432 New combined nanoparticle therapy inhibits metastatic breast tumour growth with superior efficacy and lower side effect profile to docetaxel | |
| WO2021143754A1 (zh) | 用于癌症治疗的组合及其应用 | |
| US20250122208A1 (en) | Chemokine receptor modulators and uses thereof |